Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease?

Parkinson's disease (PD) is the most common motor system disorder affecting 1-2% of people over the age of sixty-five. Although PD is generally a sporadic neurological disorder, the discovery of monogenic, hereditable forms of the disease, representing 5-10% of all cases, has been very important in helping to partially delineate the molecular pathways that lead to this pathology. These mechanisms include impairment of the intracellular protein-degradation pathways, protein aggregation, mitochondria dysfunction, oxidative stress and neuroinflammation. Some of these features are also supported by post-mortem analyses. One of the main pathological hallmarks of PD is the preferential degeneration of dopaminergic neurons, which supports a direct role of dopamine itself in promoting the disorder. This review presents a comprehensive overview of the existing literature that links the aforementioned pathways to the oxidative chemistry of dopamine, ultimately leading to the formation of free radicals and reactive quinone species. We emphasize, in particular, how the reaction of dopamine-derived quinones with several cellular targets could foster the processes involved in the pathogenesis of PD and contribute to the progression of the disorder.

[1]  W. Bodell,et al.  Detection of dopamine--DNA adducts: potential role in Parkinson's disease. , 1993, Carcinogenesis.

[2]  V. Vasiliou,et al.  Neurotoxicity and Metabolism of the Catecholamine-Derived 3,4-Dihydroxyphenylacetaldehyde and 3,4-Dihydroxyphenylglycolaldehyde: The Role of Aldehyde Dehydrogenase , 2007, Pharmacological Reviews.

[3]  E. Hirsch,et al.  Neuroinflammatory processes in Parkinson's disease. , 2005, Parkinsonism & related disorders.

[4]  L. Chin,et al.  Parkinson disease protein DJ-1 converts from a zymogen to a protease by carboxyl-terminal cleavage. , 2010, Human molecular genetics.

[5]  Minoru Harada,et al.  Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients , 1994, Neuroscience Letters.

[6]  L. Bubacco,et al.  Kinetic and Structural Analysis of the Early Oxidation Products of Dopamine , 2007, Journal of Biological Chemistry.

[7]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[8]  D. Selkoe,et al.  Dopamine covalently modifies and functionally inactivates parkin , 2005, Nature Medicine.

[9]  D. Rubinsztein,et al.  The roles of intracellular protein-degradation pathways in neurodegeneration , 2006, Nature.

[10]  T. Nagatsu,et al.  Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease , 1996, Neuroscience Letters.

[11]  M. Citron,et al.  alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. , 1999, The Journal of biological chemistry.

[12]  D. Leibfritz,et al.  Free radicals and antioxidants in normal physiological functions and human disease. , 2007, The international journal of biochemistry & cell biology.

[13]  L. Bubacco,et al.  Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease. , 2010, Biochimica et biophysica acta.

[14]  Guohua Yu,et al.  Quinoprotein Adducts Accumulate in the Substantia Nigra of Aged Rats and Correlate with Dopamine-Induced Toxicity in SH-SY5Y Cells , 2011, Neurochemical Research.

[15]  D. Goldstein,et al.  Neurodegeneration and Motor Dysfunction in Mice Lacking Cytosolic and Mitochondrial Aldehyde Dehydrogenases: Implications for Parkinson's Disease , 2012, PloS one.

[16]  D. Tucker,et al.  Morphological development of the rat heart growing in oculo in the absence of hemodynamic work load. , 1990, Circulation research.

[17]  A. Singleton,et al.  alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.

[18]  D. Standaert,et al.  Targeted Overexpression of Human &agr;-Synuclein Triggers Microglial Activation and an Adaptive Immune Response in a Mouse Model of Parkinson Disease , 2008, Journal of neuropathology and experimental neurology.

[19]  M. Gutman,et al.  Action of sulfhydryl inhibitors on different forms of the respiratory chain-linked reduced nicotinamide-adenine dinucleotide dehydrogenase. , 1970, Biochemistry.

[20]  Melinda E. Lull,et al.  Microglial activation and chronic neurodegeneration , 2010, Neurotherapeutics.

[21]  D. Tse,et al.  Potential oxidative pathways of brain catecholamines. , 1976, Journal of medicinal chemistry.

[22]  A. Carlsson,et al.  Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species , 1986, Neuropharmacology.

[23]  J. Doorn,et al.  Dopamine-derived biological reactive intermediates and protein modifications: Implications for Parkinson's disease. , 2011, Chemico-biological interactions.

[24]  S. Hunot,et al.  Neuroinflammatory processes in Parkinson's disease , 2003, Annals of neurology.

[25]  Graeme Eisenhofer,et al.  Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine , 2004, Pharmacological Reviews.

[26]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[27]  D. Sulzer,et al.  Intraneuronal dopamine-quinone synthesis: A review , 1999, Neurotoxicity Research.

[28]  M. Sturlese,et al.  Dopamine-derived Quinones Affect the Structure of the Redox Sensor DJ-1 through Modifications at Cys-106 and Cys-53* , 2012, The Journal of Biological Chemistry.

[29]  T. Nagatsu,et al.  Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. , 1996, Neuroscience letters.

[30]  D. Sulzer,et al.  Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics , 2003, Trends in Neurosciences.

[31]  Peter T Lansbury,et al.  Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. , 2008, The Journal of clinical investigation.

[32]  S. Iversen,et al.  Dopamine: 50 years in perspective , 2007, Trends in Neurosciences.

[33]  Diana Brahams,et al.  Medicine and the Law , 1983, The Lancet.

[34]  C. Shults Lewy bodies. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Cookson Parkinsonism due to mutations in PINK1, parkin, and DJ-1 and oxidative stress and mitochondrial pathways. , 2012, Cold Spring Harbor perspectives in medicine.

[36]  M. Cascio,et al.  Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: Implications for Parkinson disease , 2008, Neurobiology of Disease.

[37]  N. Hattori,et al.  Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Keith D Wilkinson,et al.  Familial Parkinson's Disease-associated L166P Mutation Disrupts DJ-1 Protein Folding and Function* , 2004, Journal of Biological Chemistry.

[39]  M. Zigmond,et al.  Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A. Lees,et al.  Conjugates of Catecholamines with Cysteine and GSH in Parkinson's Disease: Possible Mechanisms of Formation Involving Reactive Oxygen Species , 1998, Journal of neurochemistry.

[41]  C. A. D. Costa,et al.  DJ-1: a newcomer in Parkinson's disease pathology. , 2007, Current molecular medicine.

[42]  Leonidas Stefanis,et al.  Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. , 2004, Science.

[43]  Philippe Amouyel,et al.  α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[44]  G. Cohen,et al.  Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Xin Zhao,et al.  Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Cookson,et al.  Mitochondria and Dopamine New Insights into Recessive Parkinsonism , 2004, Neuron.

[47]  Philippe Amouyel,et al.  Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. , 2004, Lancet.

[48]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[49]  R. Mohney,et al.  Regional Difference in Susceptibility to Lipopolysaccharide-Induced Neurotoxicity in the Rat Brain: Role of Microglia , 2000, The Journal of Neuroscience.

[50]  Patrizia Rizzu,et al.  Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.

[51]  S. Berman,et al.  Dopamine Oxidation Alters Mitochondrial Respiration and Induces Permeability Transition in Brain Mitochondria , 1999, Journal of neurochemistry.

[52]  Roberto Cappai,et al.  Modulation of α-Synuclein Aggregation by Dopamine: A Review , 2009, Neurochemical Research.

[53]  T. Lim,et al.  Dopamine (DA) induced irreversible proteasome inhibition via DA derived quinones , 2009, Free radical research.

[54]  L. Greene,et al.  Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Peter T. Lansbury,et al.  Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.

[56]  D. Goldstein,et al.  Catechols in post‐mortem brain of patients with Parkinson disease , 2011, European journal of neurology.

[57]  Michael Cascio,et al.  Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells , 2009, Neurobiology of Disease.

[58]  M. Beal Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.

[59]  H. Ischiropoulos,et al.  Cellular Oligomerization of α-Synuclein Is Determined by the Interaction of Oxidized Catechols with a C-terminal Sequence* , 2007, Journal of Biological Chemistry.

[60]  L. Bubacco,et al.  Dopamine quinones interact with alpha-synuclein to form unstructured adducts. , 2010, Biochemical and biophysical research communications.

[61]  Jun Hu,et al.  Inhibition of α‐synuclein fibrillization by dopamine analogs via reaction with the amino groups of α‐synuclein , 2005 .

[62]  A. Reichert,et al.  Loss-of-Function of Human PINK1 Results in Mitochondrial Pathology and Can Be Rescued by Parkin , 2007, The Journal of Neuroscience.

[63]  A. Whitworth,et al.  Molecular Mechanisms of PINK1-Related Neurodegeneration , 2011, Current Neurology and Neuroscience Reports.

[64]  S. Jana,et al.  Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: implications for Parkinson's disease. , 2005, Biochimica et biophysica acta.

[65]  Jie Li,et al.  Dopamine and L‐dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[66]  H. Büeler Mitochondrial dynamics, cell death and the pathogenesis of Parkinson’s disease , 2010, Apoptosis.

[67]  G. Cohen,et al.  Monoamine Oxidase and Mitochondrial Respiration , 1999, Journal of neurochemistry.

[68]  D. Ross,et al.  A Potential Role for Cyclized Quinones Derived from Dopamine, DOPA, and 3,4-Dihydroxyphenylacetic Acid in Proteasomal Inhibition , 2006, Molecular Pharmacology.

[69]  Wenjie Xie,et al.  Microglial Activation and Dopaminergic Cell Injury: An In Vitro Model Relevant to Parkinson's Disease , 2001, The Journal of Neuroscience.

[70]  C. Perier,et al.  Neurotoxin-based models of Parkinson's disease , 2012, Neuroscience.

[71]  P. Riederer,et al.  Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. , 1994, Neuroscience letters.

[72]  C. Masters,et al.  The structure of dopamine induced α-synuclein oligomers , 2010, European Biophysics Journal.

[73]  W. Streit Microglia as neuroprotective, immunocompetent cells of the CNS , 2002, Glia.

[74]  M. Zigmond,et al.  Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. , 1997, Journal of neural transmission. Supplementum.

[75]  A. Lees,et al.  A Generalised Increase in Protein Carbonyls in the Brain in Parkinson's but Not Incidental Lewy Body Disease , 1997, Journal of neurochemistry.

[76]  E. Hirsch,et al.  Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.

[77]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[78]  Jun Hu,et al.  Inhibition of α‐synuclein fibrillization by dopamine analogs via reaction with the amino groups of α‐synuclein , 2005 .

[79]  R. Youle,et al.  Parkin-induced mitophagy in the pathogenesis of Parkinson disease , 2009, Autophagy.

[80]  F. Lee,et al.  Genetic factors involved in the pathogenesis of Parkinson's disease , 2008, Brain Research Reviews.

[81]  S. Bottomley,et al.  Dopamine promotes α‐synuclein aggregation into SDS‐resistant soluble oligomers via a distinct folding pathway , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[82]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[83]  L. Bubacco,et al.  Human SOD2 Modification by Dopamine Quinones Affects Enzymatic Activity by Promoting Its Aggregation: Possible Implications for Parkinson’s Disease , 2012, PloS one.

[84]  C. Ross,et al.  What is the role of protein aggregation in neurodegeneration? , 2005, Nature Reviews Molecular Cell Biology.

[85]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[86]  K. Vrana,et al.  Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase , 1998, Journal of neuroscience research.

[87]  E. Cavalieri,et al.  Formation of dopamine quinone‐DNA adducts and their potential role in the etiology of Parkinson's disease , 2011, IUBMB life.

[88]  D. Kuhn,et al.  Dopamine Quinones Activate Microglia and Induce a Neurotoxic Gene Expression Profile , 2006, Annals of the New York Academy of Sciences.

[89]  E. Floor,et al.  Increased Protein Oxidation in Human Substantia Nigra Pars Compacta in Comparison with Basal Ganglia and Prefrontal Cortex Measured with an Improved Dinitrophenylhydrazine Assay , 1998, Journal of neurochemistry.

[90]  Cristine Alves da Costa DJ-1: a newcomer in Parkinson's disease pathology. , 2007, Current molecular medicine.

[91]  J. Doorn,et al.  Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol. , 2009, Chemical research in toxicology.

[92]  R. Fariello,et al.  A proposed dual role of neuromelanin in the pathogenesis of Parkinson’s disease , 2006, Neurology.

[93]  E. Jayatilleke,et al.  Inhibition of brain mitochondrial respiration by dopamine: involvement of H2O2 and hydroxyl radicals but not glutathione–protein–mixed disulfides , 2002, Journal of neurochemistry.

[94]  Belinda Wilson,et al.  Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[95]  E. Masliah,et al.  Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia , 2013, Nature Communications.

[96]  M. Bulsara,et al.  Association of domestic exposure to volatile organic compounds with asthma in young children , 2004, Thorax.

[97]  M. LaVoie,et al.  Dopamine Quinone Formation and Protein Modification Associated with the Striatal Neurotoxicity of Methamphetamine: Evidence against a Role for Extracellular Dopamine , 1999, The Journal of Neuroscience.

[98]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[99]  F. Helmchen,et al.  Resting Microglial Cells Are Highly Dynamic Surveillants of Brain Parenchyma in Vivo , 2005, Science.

[100]  G. Zeevalk,et al.  Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine‐associated diseases , 2004, Journal of neurochemistry.

[101]  L. Elferink,et al.  Tyrosine Hydroxylase Is Inactivated by Catechol‐Quinones and Converted to a Redox‐Cycling Quinoprotein , 1999, Journal of neurochemistry.

[102]  K. Jellinger,et al.  Normal Mitochondrial Genome in Brain from Patients with Parkinson's Disease and Complex I Defect , 1990, Journal of neurochemistry.

[103]  A. Bentivoglio,et al.  PINK1 mutations are associated with sporadic early‐onset parkinsonism , 2004, Annals of neurology.

[104]  A. Abeliovich,et al.  DJ-1 Is a Redox-Dependent Molecular Chaperone That Inhibits α-Synuclein Aggregate Formation , 2004, PLoS biology.

[105]  Georg Auburger,et al.  The ubiquitin pathway in Parkinson's disease , 1998, Nature.

[106]  S. Ambrosio,et al.  The decrease of NAD(P)H has a prominent role in dopamine toxicity. , 2006, Biochimica et biophysica acta.

[107]  A. Schapira,et al.  Oxidative stress in Parkinson's disease , 1995, Neuropathology and applied neurobiology.

[108]  J. Trojanowski,et al.  Reversible Inhibition of α-Synuclein Fibrillization by Dopaminochrome-mediated Conformational Alterations* , 2005, Journal of Biological Chemistry.

[109]  Michael P. Murphy,et al.  How mitochondria produce reactive oxygen species , 2008, The Biochemical journal.

[110]  C. Marsden,et al.  Oxidative Stress and Parkinson's Disease a , 1996, Annals of the New York Academy of Sciences.

[111]  David N Hauser,et al.  Dopamine quinone modifies and decreases the abundance of the mitochondrial selenoprotein glutathione peroxidase 4. , 2013, Free radical biology & medicine.

[112]  L. Sanders,et al.  Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. , 2013, Free radical biology & medicine.

[113]  P. Lansbury,et al.  Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. , 2003, Biochemistry.

[114]  Steven P Gygi,et al.  The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. , 2005, Human molecular genetics.

[115]  S. Greenfield,et al.  Autoxidation of dopamine: a comparison of luminescent and spectrophotometric detection in basic solutions. , 1995, Free radical biology & medicine.

[116]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[117]  T. Montine,et al.  Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. , 1999, The American journal of pathology.